The vaccine, Pfizer’s Abrysvo, is a bivalent shot approved to prevent lower respiratory tract disease caused by RSV, according to a news release from the drugmaker.
GSK received the first approval for an RSV shot May 3 with its Arexvy vaccine.
There are no approved RSV vaccines for children, another population vulnerable to the virus.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.